Dendritic MRI contrast agents: an efficient prelabeling approach based on CuAAC

Area of Science:

• * Macromolecular chemistry
• * Nanotechnology
• * Medical imaging

Background:

• * Developing novel contrast agents (CAs) for magnetic resonance imaging (MRI) is crucial for improved diagnostics.
• * Traditional methods often yield polydisperse materials, complicating characterization and clinical application.
• * Gadolinium (Gd) chelates are widely used in MRI contrast agents.

Purpose of the Study:

• * To explore the potential of a new family of polyethylene glycol (PEG)-dendritic CAs.
• * To develop monodisperse macromolecular CAs using Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC).
• * To evaluate the in vitro and in vivo performance of these novel Gd-based dendritic CAs.

Main Methods:

• * Synthesis of PEG-dendritic CAs using a gallic acid-triethylene glycol (GATG) core.
• * Functionalization with up to 27 preformed Gd complexes via CuAAC click chemistry.
• * In vitro and in vivo evaluation of MRI contrast enhancement properties.

Main Results:

• * Efficient and complete functionalization of dendrimers achieved using CuAAC.
• * Monodisperse macromolecular CAs were successfully synthesized, contrasting with classical methods.
• * The novel dendritic CAs demonstrated MRI contrast enhancements comparable to Gadomer-17.

Conclusions:

• * CuAAC provides an efficient route to monodisperse Gd-based dendritic CAs for MRI.
• * The developed PEG-dendritic CAs represent a promising platform for clinical MRI applications.
• * Monodispersity facilitates characterization and quality control for potential clinical use.